Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pocenbrodib + darolutamide
- Development stage
- Unknown
- Lead developer
- Pathos AI
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pocenbrodib + darolutamide is an investigational combination therapy being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Pocenbrodib is an oral small-molecule inhibitor of the CREBBP (CBP) and EP300 (p300) proteins, which act as transcriptional co-activators for the androgen receptor (AR) and other oncogenic drivers. By inhibiting CBP/p300, pocenbrodib aims to overcome resistance to standard AR-targeted therapies. Darolutamide is a potent, non-steroidal androgen receptor antagonist. The combination is being studied in the Phase 1b/2a PATHWAY trial (NCT06785636) to assess safety and preliminary efficacy in patients with mCRPC.
- Other names
- PATHWAY combination
02
Targets
CREBBP (CREB-binding protein)EP300 (Histone acetyltransferase p300 (EP300) catalytic domain)AR (Adrenergic receptors)
Beyond the preview
Go deeper on pocenbrodib + darolutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pocenbrodib + darolutamide.